SUMMIT THERAPEUTICS TO HOST UTROPHIN R&D DAY 15 JUNE 2016
Oxford, UK, 8 June 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, will host a Utrophin R&D Day featuring presentations from three DMD key opinion leaders alongside Summit's management on 15 June 2016 in New York City.
This event is open to analysts, institutional investors and members of the press. For more information, email firstname.lastname@example.org.
A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.